Sort   by:  
 Page size 
UnknownCOVID-19: from epidemiology to treatment.
Not available
S-EPMC7279517 | biostudies-literature
UnknownA 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies.
Not available
S-EPMC10924177 | biostudies-literature
UnknownFirst-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817.
Not available
S-EPMC9896179 | biostudies-literature
UnknownClinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis.
Not available
S-EPMC12130808 | biostudies-literature
UnknownConsistent improvement with eculizumab across muscle groups in myasthenia gravis.
Not available
S-EPMC7448154 | biostudies-literature
UnknownInfluence of vancomycin minimum inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus left-sided infective endocarditis treated with antistaphylococcal β-lactam antibiotics: a prospective cohort study by the International Collaboration on Endocarditis.
Not available
S-EPMC5816984 | biostudies-literature
UnknownEculizumab improves fatigue in refractory generalized myasthenia gravis.
Not available
S-EPMC6620379 | biostudies-literature
UnknownDurvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Not available
S-EPMC7771363 | biostudies-literature
Unknown'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab.
Not available
S-EPMC7320935 | biostudies-literature
UnknownPost-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension.
Not available
S-EPMC7905790 | biostudies-literature
Sort   by:  
 Page size